Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21,935 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy.
Okuma Y, Ko R, Shukuya T, Tateishi K, Imai H, Iwasawa S, Miyauchi E, Kojima T, Fujita Y, Hino T, Yamanda S, Suzuki T, Fukuizumi A, Sakakibara T, Harada T, Morita S, Kobayashi K, Nukiwa T, Takahashi K; North East Japan Study Group. Okuma Y, et al. Among authors: suzuki t. Lung Cancer. 2020 Oct;148:122-128. doi: 10.1016/j.lungcan.2020.08.014. Epub 2020 Aug 20. Lung Cancer. 2020. PMID: 32890794
Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
Morikawa N, Inoue A, Sugawara S, Maemondo M, Harada T, Harada M, Fujita Y, Katoh T, Yokouchi H, Watanabe H, Usui K, Suzuki T, Sakakibara-Konishi J, Nagai H, Kanbe M, Nukiwa T. Morikawa N, et al. Among authors: suzuki t. Lung Cancer. 2017 Sep;111:38-42. doi: 10.1016/j.lungcan.2017.06.016. Epub 2017 Jul 1. Lung Cancer. 2017. PMID: 28838395 Clinical Trial.
Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Inoue A, Sugawara S, Maemondo M, Mori Y, Oizumi S, Harada M, Taima K, Morikawa N, Ishida T, Kinoshita I, Watanabe H, Suzuki T, Nakagawa T, Saito R, Nukiwa T. Inoue A, et al. Among authors: suzuki t. Lung Cancer. 2015 Jul;89(1):61-5. doi: 10.1016/j.lungcan.2015.04.012. Epub 2015 May 4. Lung Cancer. 2015. PMID: 26004087 Clinical Trial.
Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
Miyauchi E, Inoue A, Usui K, Sugawara S, Maemondo M, Saito H, Fujita Y, Kato T, Suzuki T, Harada T, Watanabe H, Nakagawa T, Ichinose M. Miyauchi E, et al. Among authors: suzuki t. Oncologist. 2017 Jun;22(6):640-e59. doi: 10.1634/theoncologist.2017-0059. Epub 2017 May 19. Oncologist. 2017. PMID: 28526722 Free PMC article. Clinical Trial.
Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.
Kawashima Y, Inoue A, Sugawara S, Oizumi S, Maemondo M, Okudera K, Suzuki T, Usui K, Harada M, Morikawa N, Hasegawa Y, Saito R, Ishimoto O, Sakakibara T, Asahina H, Nukiwa T. Kawashima Y, et al. Among authors: suzuki t. Respir Investig. 2014 May;52(3):190-4. doi: 10.1016/j.resinv.2013.12.005. Epub 2014 Jan 28. Respir Investig. 2014. PMID: 24853020 Clinical Trial.
Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab.
Nihei S, Sato J, Harada T, Kuyama S, Suzuki T, Waga N, Saito Y, Kisara S, Yokota A, Okada K, Tsuchiya M, Terui K, Tadokoro Y, Chiba T, Kudo K, Oizumi S, Inoue A, Morikawa N. Nihei S, et al. Among authors: suzuki t. Cancer Chemother Pharmacol. 2018 Jun;81(6):1051-1059. doi: 10.1007/s00280-018-3580-1. Epub 2018 Apr 12. Cancer Chemother Pharmacol. 2018. PMID: 29651572
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, Watanabe H, Tsukamoto T, Saijo Y, Ishimoto O, Hommura F, Nukiwa T. Inoue A, et al. Among authors: suzuki t. J Clin Oncol. 2008 Nov 20;26(33):5401-6. doi: 10.1200/JCO.2008.18.1974. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854562 Clinical Trial.
Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.
Koizumi T, Agatsuma T, Ikegami K, Suzuki T, Kobayashi T, Kanda S, Yoshikawa S, Kubo K, Shiina T, Takasuna K, Matsuo A, Hayasaka M, Morikawa M, Ameshima S. Koizumi T, et al. Among authors: suzuki t. Clin Lung Cancer. 2012 Nov;13(6):458-63. doi: 10.1016/j.cllc.2012.01.006. Epub 2012 Mar 7. Clin Lung Cancer. 2012. PMID: 22402083 Clinical Trial.
Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study.
Wada Y, Koyama S, Kuraishi H, Miyahara T, Yoshiike F, Agatsuma T, Yamamoto R, Ono Y, Suzuki T, Hachiya T, Gomi D, Tateishi K, Hanaoka M, Koizumi T. Wada Y, et al. Among authors: suzuki t. Respir Investig. 2016 Nov;54(6):462-467. doi: 10.1016/j.resinv.2016.07.003. Epub 2016 Aug 25. Respir Investig. 2016. PMID: 27886858
21,935 results
You have reached the last available page of results. Please see the User Guide for more information.